Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis “Nutra NMA SCZ”-Reference-Cited by-同舟云学术

Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis “Nutra NMA SCZ”

Published:2024-07-18 Issue: Volume: Page:
ISSN:1359-4184
Container-title:Molecular Psychiatry
language:en
Short-container-title:Mol Psychiatry

Author:

Fornaro Michele^ORCID,Caiazza Claudio,Billeci Martina,Berk Michael,Marx Wolfgang^ORCID,Balanzá-Martinez Vicent,De Prisco Michele^ORCID,Pezone Rosanna,De Simone Giuseppe^ORCID,Solini Niccolò,Iasevoli Felice,Berna Fabrice,Fond Guillaume^ORCID,Boyer Laurent^ORCID,Carvalho Andre Fèrrer^ORCID,Dragioti Elena,FIEDOROWICZ Jess G.^ORCID,de Bartolomeis Andrea^ORCID,Correll Christoph U.^ORCID,Solmi Marco^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41380-024-02645-y.pdf

Reference95 articles.

1. GBD 2019 MDC. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9:137–50.

2. Solmi M SG, Mavridis D, Correll CU, Dragioti E, Guimond S, et al. Incidence, prevalence, and global burden of schizophrenia—data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Mol Psychiatry. 2023.

3. Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177:868–72.

4. Correll CU, Howes OD. Treatment-resistant schizophrenia: definition, predictors, and therapy options. J Clin Psychiatry. 2021; 82:MY20096AH1C.

5. Diniz E, Fonseca L, Rocha D, Trevizol A, Cerqueira R, Ortiz B, et al. Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates. Braz J Psychiatry. 2023;45:448–58.